http://orcid.org/0000-0002-4350-2276
Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Ernesto Rossi, Giovanni Schinzari, Brigida Anna Maiorano, Giulia Indellicati, Alessandro Di Stefani, Monica Maria Pagliara, Simona Maria Fragomeni, Erika Valentina De Luca, Maria Grazia Sammarco, Giorgia Garganese, Jacopo Galli, Maria Antonietta Blasi, Gaetano Paludetti, Giovanni Scambia, Ketty Peris & Giampaolo Tortora. (2021) Efficacy of immune checkpoint inhibitors in different types of melanoma. Human Vaccines & Immunotherapeutics 17:1, pages 4-13.
Read now
Read now
Yongshuai Jiang, Ming Chen, Hong Nie & Yuanyang Yuan. (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines & Immunotherapeutics 15:5, pages 1111-1122.
Read now
Read now
Paolo A. Ascierto & Reinhard Dummer. (2018) Immunological effects of BRAF+MEK inhibition. OncoImmunology 7:9.
Read now
Read now
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology 7:6.
Read now
Read now
Carole Fournier, François Martin, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Lionel Apetoh. (2017) Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology 6:11.
Read now
Read now
Articles from other publishers (26)
Shixin Zhao, Yongkang Zhu, Hengdeng Liu, Xuefeng He & Julin Xie. (2023) System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma. Journal of Translational Medicine 21:1.
Crossref
Crossref
Claudia Trojaniello, Francesca Sparano, Eleonora Cioli & Paolo Antonio Ascierto. (2023) Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned. Current Oncology Reports 25:6, pages 623-634.
Crossref
Crossref
Maximilian Haist, Henner Stege, Michael Kuske, Julia Bauer, Annika Klumpp, Stephan Grabbe & Matthias Bros. (2023) Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews 42:2, pages 481-505.
Crossref
Crossref
Gabriele Romano, Francesca Paradiso, Peng Li, Pooja Shukla, Lindsay N. Barger, Olivia El Naggar, John P. Miller, Roger J. Liang, Timothy L. Helms, Alexander J. Lazar, Jennifer A. Wargo, Francesca Taraballi, James C. Costello & Lawrence N. Kwong. (2023) Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunology Research 11:5, pages 558-569.
Crossref
Crossref
Paolo A. Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer & Vanna Chiarion Sileni. (2023)
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated
BRAF
-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
. Journal of Clinical Oncology 41:2, pages 212-221.
Crossref
Crossref
Marta Morante, Atanasio Pandiella, Piero Crespo & Ana Herrero. (2022) Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. Biomolecules 12:11, pages 1562.
Crossref
Crossref
Fazal Dalal, Hussain Dalal & Brad Baltz. (2022) Pembrolizumab-Induced Myocarditis and Delayed Acute Inflammatory Demyelinating Polyradiculoneuropathy. Cureus.
Crossref
Crossref
Paweł Rogala, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, Joanna Seredyńska, Wiesław Bal, Katarzyna Kozak, Anna Surus-Hyla, Tomasz Kubiatowski, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz & Piotr Rutkowski. (2022) Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. Cancers 14:9, pages 2123.
Crossref
Crossref
Maximilian Haist, Henner Stege, Ronja Ebner, Maria Isabel Fleischer, Carmen Loquai & Stephan Grabbe. (2022) The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. Cancers 14:9, pages 2082.
Crossref
Crossref
Paweł Rogala, Anna M. Czarnecka, Bożena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Ziętek, Robert Dziura, Ewa Rutkowska, Łukasz Galus, Natasza Kempa-Kamińska, Jacek Calik, Agata Sałek-Zań, Tomasz Zemełka, Wiesław Bal, Agnieszka Kamycka, Tomasz Świtaj, Grażyna Kamińska-Winciorek, Rafał Suwiński, Jacek Mackiewicz & Piotr Rutkowski. (2022) Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. Journal of Clinical Medicine 11:8, pages 2239.
Crossref
Crossref
Adrian Barreno & Jose L. Orgaz. (2022) Cytoskeletal Remodelling as an Achilles’ Heel for Therapy Resistance in Melanoma. Cells 11:3, pages 518.
Crossref
Crossref
Yujue Wang, Sixue Liu, Zhentao Yang, Alain P. Algazi, Shirley H. Lomeli, Yan Wang, Megan Othus, Aayoung Hong, Xiaoyan Wang, Chris E. Randolph, Alexis M. Jones, Marcus W. Bosenberg, Stephanie D. Byrum, Alan J. Tackett, Henry Lopez, Clayton Yates, David B. Solit, Antoni Ribas, Marco Piva, Gatien Moriceau & Roger S. Lo. (2021) Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell 39:10, pages 1375-1387.e6.
Crossref
Crossref
X. Bai & K.T. Flaherty. (2020)
Targeted and immunotherapies in
BRAF
mutant melanoma: where we stand and what to expect
. British Journal of Dermatology 185:2, pages 253-262.
Crossref
Crossref
Emily J. Lelliott, Grant A. McArthur, Jane Oliaro & Karen E. Sheppard. (2021) Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. Frontiers in Immunology 12.
Crossref
Crossref
Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun & Brigitte Dréno. (2020) Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. Journal of Translational Medicine 18:1.
Crossref
Crossref
Patryk Górniak, Maja Wasylecka‐Juszczyńska, Iwona Ługowska, Piotr Rutkowski, Anna Polak, Maciej Szydłowski & Przemysław Juszczyński. (2020) BRAF inhibition curtails IFN‐gamma‐inducible PD‐L1 expression and upregulates the immunoregulatory protein galectin‐1 in melanoma cells. Molecular Oncology 14:8, pages 1817-1832.
Crossref
Crossref
Igor Puzanov, Antoni Ribas, Caroline Robert, Jacob Schachter, Marta Nyakas, Adil Daud, Ana Arance, Matteo S. Carlino, Steven J. O’Day, Georgina V. Long, Kim A. Margolin, Reinhard Dummer, Dirk Schadendorf, Jose Lutzky, Paolo A. Ascierto, Ahmad Tarhini, Jianxin Lin, Robin Mogg, Blanca Homet Moreno, Nageatte Ibrahim & Omid Hamid. (2020)
Association of
BRAF
V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma
. JAMA Oncology 6:8, pages 1256.
Crossref
Crossref
Irene L. M. Reijers, Elisa A. Rozeman, Sofie Wilgenhof, Johannes V. Thienen, John B. A. G. Haanen & Christian U. Blank. (2019) Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma. Pigment Cell & Melanoma Research 33:3, pages 498-506.
Crossref
Crossref
Pauline Tétu, Barouyr Baroudjian & Céleste Lebbe. (2020) Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. Current Opinion in Oncology 32:2, pages 85-90.
Crossref
Crossref
Paolo A. Ascierto & Michael B. Atkins. 2020. Cutaneous Melanoma. Cutaneous Melanoma
1215
1241
.
Vito Vanella, Lucia Festino, Claudia Trojaniello, Maria Grazia Vitale, Antonio Sorrentino, Miriam Paone & Paolo A. Ascierto. (2019) The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Current Oncology Reports 21:9.
Crossref
Crossref
Sophia Kreft, Anja Gesierich, Thomas Eigentler, Cindy Franklin, Sara Valpione, Selma Ugurel, Jochen Utikal, Sebastian Haferkamp, Christian Blank, James Larkin, Claus Garbe, Dirk Schadendorf, Paul Lorigan & Bastian Schilling. (2019) Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. European Journal of Cancer 116, pages 207-215.
Crossref
Crossref
Meredith S. Pelster & Rodabe N. Amaria. (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Therapeutic Advances in Medical Oncology 11, pages 175883591983082.
Crossref
Crossref
Svenja Meierjohann & Bastian Schilling. 2019. Oncogenomics. Oncogenomics
655
668
.
Paolo A. Ascierto & Michael B. Atkins. 2018. Cutaneous Melanoma. Cutaneous Melanoma
1
27
.
M. Amini-Adle, N. Khanafer, M. Le-Bouar, G. Duru, S. Dalle & L. Thomas. (2018) Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma. BMC Cancer 18:1.
Crossref
Crossref